Secondary Endothelial Keratoplasty—A Narrative Review of the Outcomes of Secondary Corneal Endothelial Allografts

Nuno Moura-Coelho, MD, MMed,[1,2,3] João Paulo Cunha, MD, PhD,[4,5] Merce Morral, MD, PhD,[6,7] Oscar Gris, MD, PhD,[6,7] Felicidad Manero, MD,[6,7] and José Luis Güell, MD, PhD[6,7]

Background. We review the literature on the efficacy and safety outcomes of secondary Descemet stripping endothelial keratoplasty (DSEK) and Descemet membrane endothelial keratoplasty (DMEK). **Methods.** Literature search of English-written publications up to September 27, 2020 in PubMed database, using the terms "endothelial keratoplasty" in combination with keywords "secondary" or "repeat." In addition, we manually searched the references of the primary articles. **Results.** Twenty-seven studies (n = 651 eyes) were retained and reviewed, including 10 studies on repeat DSEK, 8 studies on repeat DMEK, 6 studies of DMEK following DSEK, and 3 studies of DSEK after failed DMEK. All studies reported significant improvement in visual acuity after secondary endothelial keratoplasty (EK). Twelve studies compared visual outcomes between primary and secondary EK, reporting conflicting findings. Sixteen studies reported endothelial cell loss rates after secondary EK, and only 1 study reported significantly increased endothelial cell loss rates compared with primary EK. Allograft rejection episodes occurred in 1.8% of eyes (range, 0%–50%). Six studies compared complication rates between primary and secondary EK eyes, and only 1 study found a higher median number of complications. However, 2 studies reported higher regraft failure rates compared with primary EK eyes. **Conclusions.** Secondary EK is surgically feasible and renders significant visual improvement after failed primary EK, although it is not clear whether visual outcomes and allograft survival are comparable with primary EK, raising the question of whether secondary EK eyes are "low risk" as primary EK eyes. Further larger, prospective studies are encouraged to obtain additional quality data on secondary corneal endothelial allotransplantation.

(*Transplantation* 2021;105: e347–e365).

INTRODUCTION

Posterior lamellar keratoplasty, including Descemet stripping membrane endothelial keratoplasty (DSEK) and Descemet membrane endothelial keratoplasty (DMEK), has significantly progressed in the last decade, and endothelial keratoplasty (EK) techniques have superseded penetrating keratoplasty (PKP) as the corneal allograft transplantation techniques of choice in the management of corneal endothelial disease (Figure 1).[1-3] Primary or secondary corneal endothelial cell (CEC) failure is currently the main indication for corneal transplantation worldwide, representing 56% of all corneal transplants in the United States[2]; of these, 90% were EK grafts and only 10% were PKP grafts.[2] PKP may still be indicated in certain cases of primary or secondary corneal endothelial disease, particularly in eyes with significant corneal subepithelial or stromal scarring,

Received 10 October 2020. Revision received 11 February 2021.

Accepted 14 February 2021.

[1] Department of Ophthalmology, Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.

[2] NOVA Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, Portugal.

[3] Department of Ophthalmology, Instituto Português de Retina, Lisbon, Portugal.

[4] Department of Ophthalmology, Hospital CUF Cascais, Cascais, Portugal.

[5] Department of Ophthalmology, Escola Superior de Tecnologia da Saúde de Lisboa do Instituto Politécnico de Lisboa, Lisbon, Portugal.

[6] Cornea and Refractive Surgery Department, Instituto Microcirugía Ocular Barcelona, Barcelona, Spain.

[7] Ophthalmology Department, Universidad Autónoma de Barcelona, Barcelona, Spain.

The authors declare no funding or conflicts of interest.

N.M-.C. participated in conceptualization, methodology, research design, writing of the original draft, writing, reviewing, editing, and data analysis. J.P.C. participated in writing of the article, reviewing, editing, and supervision. M.M. participated in writing of the article, reviewing, editing, and validation. O.G. participated in supervision and validation. F.M. participated in data collection, writing of the original draft, validation, and supervision. J.G. participated in conceptualization, methodology, writing, reviewing, editing, supervision, and validation.

Online Supplemental Appendix; http://links.lww.com/TP/C177 and Supplemental Glossary Terms; http://links.lww.com/TP/C233.

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.transplantjournal.com).

Correspondence: Nuno Moura-Coelho, MD, MMed, Ophthalmology Department, Centro Hospitalar Universitário Lisboa Central, Rua José António Serrano, 1150-199 Lisbon, Portugal. (nunomouracoelho.oft@gmail.com).

ISSN: 0041-1337/20/10512-e347

DOI: 10.1097/TP.0000000000003735

<zdoi;10.1097/TP.0000000000003735>



FIGURE 1. Schematic representation of the corneal allograft transplant procedures, including PKP and PLK techniques. In PKP (top left), the full-thickness of the recipient cornea composed of epithelium and Bowman's membrane (light green), corneal stroma (blue) and endothelial layer, and Descemet's membrane (dark green) is trephined and replaced by a full-thickness donor corneal allograft. In DLEK (top middle), an early PLK technique no longer in use, a posterior lamellar disc composed of endothelium, Descemet's membrane, and posterior stroma is manually dissected from the recipient cornea through a 9-mm sclerocorneal incision and replaced by an equally sized donor disc, placed against the recipient posterior cornea with an air bubble. In DSEK (top right), the EDM is stripped from the recipient cornea, and is replaced with a donor allograft composed of EDM, plus posterior stroma of variable thickness using a manual dissection or automatic dissection with a microkeratome (DSAEK). In ultrathin DSAEK (bottom left), the donor lenticule thickness is <100 μm owing to decreased stromal thickness, which may improve visual outcomes compared with the "conventional" DSEK techniques. In DMEK (bottom middle), the recipient's EDM complex is replaced only by donor Descemet's and endothelium. Donor lenticule grafts in DSEK and DMEK are positioned against the recipient's posterior stroma with air or with 20% sulfur hexafluoride and may be at risk of graft detachment (bottom right). DLEK, deep lamellar endothelial keratoplasty; DMEK, Descemet membrane endothelial keratoplasty; DSAEK, Descemet stripping automated endothelial keratoplasty; DSEK, Descemet stripping endothelial keratoplasty; EDM, endothelial-Descemet's complex; PKP, penetrating keratoplasty; PLK, posterior lamellar keratoplasty.

where outcomes of EK may be suboptimal.[4] Although an increasing body of evidence favors DMEK over DSEK in terms of efficacy and safety,[5] DSEK may have a lower rate of rebubbling,[5] and is still the most performed EK surgery among corneal specialists worldwide.[2,6]

Graft Failure After Endothelial Keratoplasty

In contrast to other forms of allogeneic transplantation, primary corneal allografts are regarded as having high long-term success rates. However, graft failure is a potential complication following EK, as may occur after PKP grafts. The causes of failed EK grafts have been classified as either primary graft failure (PGF) or secondary graft failure. The most common cause of secondary graft failure is late endothelial graft failure (LEGF),[7,8] followed by immune rejection and glaucoma; other causes include infection, trauma, and epithelial ingrowth. The graft survival rate decreases with time, with reported mean survival rates after DMEK ranging from 83% to 96% at 5 y[9-11] and 79% at 10 y[11] and reported mean 5-y survival rates following DSEK ranging from 79.4% to 96% at 5 y.[12-15]

PGF has been defined as the absence of corneal clearing within 2 mo following EK. This may occur because of significant iatrogenic CEC loss during the preparation, insertion, or manipulation of the graft; because of "upside-down" graft (particularly during the early y of the technique or during the surgical learning curve) or because of graft detachment (GD). Reported rates of PGF ranges from 0% to 12.5% after DMEK,[8] 0%–29% after DSEK,[16] and 1.4% after ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK),[17] with a lower average PGF rate in favor of DMEK.[8] In the Cornea Preservation Time Study (CPTS), a benchmark study that analyzed the outcomes following DSEK, risk factors for primary or early failure following DSEK included patient-related factors (notably preoperative diagnosis of pseudophakic or aphakic corneal edema), donor-related factors (notably diabetes mellitus), and operative factors.[18]

GD occurs more commonly with DMEK compared with DSEK,[5,8] with mean reported rebubbling rates of 28.8% versus 14% in favor of DSEK.[8] Reported factors associated with decreased risk of GD following DMEK include increased surgeon experience, a larger descemetorhexis, the use of 20% sulfur hexafluoride (SF6) instead of air, a normal intraocular pressure (IOP), and a well-centered graft.[8,19,20] History of donor diabetes, increased prelamellar dissection central corneal thickness, and intraoperative complications have been identified as predictive factors for GD in the CPTS.[21] It has been suggested that GD is associated with increased EC loss following DSEK and therefore may decrease graft survival.[20] Rebubbling following GD achieves graft adhesion in a high percentage of patients in both DSEK and DMEK, but even in cases of successfully reattached grafts, 31%–35% of DSEK grafts still evolve to PGF.[22,23] Rebubbling for detached DMEK grafts has a definitive benefit and may allow similar visual outcomes as in uncomplicated DMEK and should usually be performed early.[24] However, the decision and timing of rebubbling for detached DMEK graft must be carefully considered, because prolonged air tamponade following rebubbling causes increased, IOP-independent CEC loss.[22,24,25]

Progressive CEC loss after EK is associated with reduced graft survival and LEGF. Following uncomplicated EK, the reported mean 6-mo endothelial cell loss rate (%ECL) ranges from 24% to 37% following DMEK, DSEK, or UT-DSAEK,[8-10,26,27] and the evidence of significant differences in %ECL between EK techniques is inconclusive.[25] The CEC loss after EK has a linear profile in the medium and long terms.[11,28] Mean rates of CEC loss after conventional DSEK/DSAEK range from 36% to 43% after

3 y,[29] 48.7%–55% after 5 y[12,14,30] (comparable with UT-DSAEK[17]), and 71% after 10 y.[28] Rates of CEC loss after DMEK range from 48% to 59% at 5 y,[9,11,31] and 1 study reported a mean 68% EC loss at 10-y follow-up.[11] The cumulative probability of LEGF after DSEK was 1.3% at 3 y in the CPTS,[32] and the cumulative probability of survival at 5 y ranges from 79.4% to 96%.[12-15] The average rate of LEGF after DMEK (follow-up times between 6 mo and 8 y) is 2.2%,[8] with 1 study reporting a 6% rate of LEGF at 10-y follow-up,[11] and the graft 5-y survival probability ranges from 83% to 96%.[9-11] Compared with PKP grafting, the CEC loss rate following EK is higher in the first 6–12 mo postoperative, mostly due to manipulation of the graft during surgery. However, the CEC loss is comparable between EK and PKP after 3 y of follow-up,[33] and over the long term, the CEC loss in PKP grafts is greater than with EK grafts. In the Cornea Donor Study, a benchmark study reporting outcomes following PKP, the median CEC loss rates at 5- and 10-y follow-up after PKP were 69%–75% (in contrast with 48%–59% after EK) and 76% to 79% (versus 68–71% for EK), respectively.[34,35]

EK is regarded as a low-risk setting for allograft rejection episodes, with significantly lower rejection rates compared with PKP.[8,16,36] Mean rejection rates are 10% (range, 0%–45%) following DSEK (follow-up times between 6 mo and 8 y)[8] and 1.9% (range, 0%–5.9%) after DMEK (follow-up times between 6 mo and 10 y)[8,11]; the 5-y risk of rejection after DMEK may be as much as 71% lower than for DSEK.[31] The 5-y cumulative probability of rejection episodes after UT-DSAEK was 6.9%.[17] The rejection rates following EK grafting are significantly lower compared with those of PKP, in which overall 30% may experience at least 1 episode of immune reaction.[37] We refer the reader to a comprehensive review on the immune mechanisms after modern lamellar keratoplasty for further detail on the clinical and pathogenic mechanisms involved in corneal allograft rejection.[38]

Rejection episodes may be a predictive factor for graft failure or need of graft exchange after EK,[15,39,40] although this is not consensual.[31,41] In the setting of PKP, about one-third of grafts with history of at least 1 episode of allograft rejection will eventually fail.[37] There is significant variation in the reported risk of graft failure after immune rejection after DSEK. In the CPTS, the cumulative probability of rejection was 3.6% 3 y after DSEK, and 27% of eyes with definite graft rejection subsequently failed.[39]

Secondary Endothelial Keratoplasty

Repeat keratoplasty has become an increasing indication for corneal transplantation, being the fourth most frequent indication in the United States (13% of all corneal transplant procedures performed in 2019).[2] Repeat keratoplasty has a long track record of safety and efficacy in eyes with previously failed PKP grafts (repeat PKP),[42] but secondary PKP grafts are considered high-risk cases because of increased risk of rejection and failure. In the Collaborative Corneal Transplantation Studies, a benchmark study in the field of corneal allogeneic transplantation, the number of previous PKP grafts was a strong risk factor for graft failure, with a 1.2-fold increased risk with each additional graft.[43] Five-year graft survival after primary PKP is 92%–95% and decreases sequentially with each regraft (79%–82% after secondary graft, 54%–71% after tertiary graft, and 42%–56% after ≥4 grafts).[6,44] Allograft rejection after PKP occurs earlier with a more fulminant course in regrafts that in primary grafts, and the risk of regraft failure is especially high if previous graft failure was a result of an allograft rejection.[45]A number of factors contribute to increased risk of immunological rejection in the setting of repeat PKP allografts,[46] including previous alloimmune response (regraft-associated sensitization) and residua of the previous surgery such as corneal neovascularization and peripheral anterior synechiae.[4]

EK is becoming increasingly indicated in retransplantation, with estimated regraft rates of 10% in the United States and 14% worldwide.[2] In the setting of failed primary PKP graft, EK has proven to be a safe and effective technique.[47-53] A recent meta-analysis found that eyes undergoing EK for failed PKP graft had a significantly lower risk of graft rejection compared with eyes undergoing repeat PKP.[54] In our cohort of eyes undergoing DMEK after failed PKP graft,[51] we found a significant improvement in visual acuity and a high rate of clear corneal grafts at 2-y follow-up; we have however recently documented 1 case of DMEK graft rejection failure after PKP, which ended in graft failure requiring repeat DMEK.[55]

In eyes with failed primary EK grafts or cases of "suboptimal DSEK" (DSEK eyes with poor visual outcomes), secondary EK has been proposed as a potentially safe and effective strategy. Zafar et al[56] have reported an overall probability of receiving a repeat EK of 6.1% at 6 mo and 16.9% at 8 y. In this large retrospective study, younger age, male gender, Asian or melanodermic ethnicity, glaucoma diagnosis, prior or concurrent glaucoma surgery, macular pathology, prior anterior segment surgeries, and lower surgeon volume were found to be factors associated with increased risk of repeat EK.[56] Regrafts were also at increased risk of repeat EK in their study.[56]

In this study, we provide a qualitative literature review on the techniques, efficacy, and safety of secondary EK.

MATERIALS AND METHODS

We conducted a literature search in the PubMed database to assess the functional outcomes following secondary EK. We searched English-written publications up to September 27, 2020, using the following query: "Endothelial keratoplasty"[Title/Abstract] AND ("secondary"[Title/Abstract] OR "repeat"[Title/Abstract]). To reduce the chance of missing relevant articles, we searched manually the references of the primary articles. We included case reports, case-control, cross-sectional, retrospective, or prospective studies, including studies in which the patient groups included EK and PKP eyes, in which we analyzed the secondary EK eye group only. We excluded studies in which the aim of the study was not assessing functional outcomes (visual acuity, graft failure). We also excluded studies of secondary EK for previously failed deep lamellar EK, as this technique has been superseded by DSEK and DMEK. After removing duplicate records, we independently screened the titles, abstract, and keywords to identify relevant articles in secondary EK (DSEK/DSAEK or DMEK). Studies not related to secondary DSEK or secondary DMEK were excluded.

We performed a qualitative analysis of the full-text articles assessed. We assessed 358 articles for eligibility (356

from PubMed database and 2 articles by manual search of primary articles) and selected all the original studies (case reports, case series, and comparative studies) that reported the results following secondary EK to include in the analysis. We excluded conference abstracts, editorials and letters to the editor, irrelevant records, nonhuman studies, and review articles. We independently extracted data into a customized database. We analyzed the outcomes of secondary EK according to type of primary and secondary EK surgeries (repeat DSEK, repeat DMEK, DMEK after failed primary DSEK, and DSEK after failed primary DMEK). The extracted information included authors of the study, publication year and journal, sample size (number of eyes), indication for secondary EK and proportion of eyes undergoing primary EK for Fuchs endothelial corneal dystrophy, time between primary and secondary grafts, preoperative corrected distance visual acuity (CDVA), postoperative follow-up time, and final CDVA. When reported, we also extracted information regarding the surgical technique, %ECL, complication rates (rebubbling for GD, allograft rejection, other complications), and rate of regraft failure.

RESULTS

We found 27 studies reporting outcomes following secondary EK (n = 651 eyes). The study by Yazu et al[57] was excluded because visual outcomes were not reported following repeat DSEK. We excluded the studies by Dirisamer et al[58] and by Kim et al[59] because they reported outcomes of DSEK after failed deep lamellar EK, an earlier technique of corneal endothelial transplantation which has fallen into disuse. Finally, we excluded the study by Agha et al[60] because the same group had published 2 different comparative case series on repeat DMEK and repeat DSAEK in the same year with larger cohorts.

Repeat DSEK

Ten studies (n = 403 eyes) analyzed the outcomes of repeat DSEK (re-DSEK).[61-70] The 2 main indications for re-DSEK were failed primary DSEK graft and poor visual performance after primary DSEK. Prior aqueous shunt surgery, donor graft CEC density, and at least 1 documented postoperative rejection episode were the main factors associated with the need for DSEK graft exchange after primary DSEK in a multivariable model.[40]

Two re-DSEK studies included eyes with suboptimal primary DSEK64,67; the proportion of eyes that had re-DSEK for this indication was highly variable, ranging from 1.9% to 76% (Table 1).[63,66] Even in eyes with clear primary DSEK grafts, final CDVA is variable, with a mean postoperative CDVA of 20/40–20/30 at 3–6 mo following DSEK or ultrathin DSEK (UT-DSEK), and % eyes reaching CDVA ≥20/40 ranging from 38% to 100%.[16,71] In addition, the proportion of eyes reaching CDVA ≥20/25 following DSEK was relatively low (6%–31%). Poor visual recovery after primary DSEK can occur in eyes with clear grafts due to interface abnormalities or significant wrinkles and folds in the pupillary area.[63] The latter has been hypothesized to be the result of mismatch between donor and recipient corneal curvatures.[63] Proposed abnormalities contributing to poorer visual performance following DSEK include increased corneal aberrations of the posterior surface,[72,73] and increased light scattering at the host-donor interface, which may be due to host Descemet's membrane (DM) remnants, presence of interface material such as fibrocellular tissue including cytokeratin, fibronectin, and vimentin,[74] or stromal contraction of the donor graft.[75] Graft thickness is likely to influence visual outcomes following DSEK, and this has been one argument favoring UT-DSEK over conventional DSEK27; however, this remains controversial.[76] Interestingly, DMEK has been demonstrated to result in fewer posterior corneal aberrations compared with conventional DSEK and UT-DSEK.[73,77]

Repeat DSEK can be performed under sub-Tenon or retrobulbar anesthesia supplemented with neuroleptic anesthesia. Repeat DSEK is performed through the same incision site as the primary DSEK procedure by opening the original incision with a keratome. The failed DSEK donor graft can be removed using a reverse Sinskey hook to detach it from the recipient corneal stroma engaging the edge of the graft[63,64] or alternatively using a bent 27-gauge needle inserted through the limbus at the 12-o'clock position,[66] and then removed from the anterior chamber (AC) using an intraocular forceps. It is important to make sure the graft has not adhered to the iris, as these adhesions may be quite dense with thick membranes that may lead to iris dehiscence upon graft removal.[78] The new donor graft is prepared as for standard primary DSEK or UT-DSEK, but the lenticule diameter should be the same or slightly larger than the previous failed DSEK graft. The lenticule insertion and AC filling techniques are the same as for the primary DSEK procedure.[64,66] Interestingly, secondary DSAEK has anecdotally been performed without removal of the failed DSAEK graft in a recent case report, with successful improvement of pain and corneal edema in a painful red eye with bullous keratopathy and poor vision.[79] Matsumoto et al[69] have reported repeat DSAEK to render successful anatomical and functional results in combination with phakic intraocular lens (IOL) explantation and cataract surgery.

The standard postoperative regimens following re-DSEK include topical tobramycin 0.3% eye drops for 4 wk; proposed topical corticosteroid regimen varies between surgeons, but maintenance therapy with a topical steroid over a long period is a common aspect.[64,66] Systemic prednisolone (1.5 mg/kg body weight with tapering over 3 mo) has been considered in cases of DSEK failure due to allograft rejection.[66]

Most eyes can expect clear functioning and improvement in CDVA following re-DSEK. CDVA improved in 97% of eyes that underwent re-DSEK for poor visual performance.[63] Reported visual outcomes seem to be similar to those achieved for primary DSEK surgery,[67] with mean CDVA after re-DSEK ranging from 0.50 to 0.18 logMAR (Snellen equivalent 20/30–20/63).[63,64,66,70] Besides, maximal postoperative CDVA after re-DSEK reported rates of eyes reaching CDVA ≥20/40 following re-DSEK ranges from 20% to 100%.[62-64] If studies with ≤2 eyes were excluded from this analysis, then the proportion of eyes reaching CDVA ≥20/40 would be 20%–82%, and no studies observed eyes reaching CDVA ≥20/25.[62] Visual results in these eyes are negatively influenced by high-order aberrations of the posterior corneal surface[57] and positively influenced by a higher preoperative IOP before re-DSEK.[68]

Rates of CEC loss were reported in 3 studies (n = 192 eyes), ranging from 36.7% to 47.3% (follow-up times

TABLE 1.

Outcomes of repeat DSEK reported in the literature

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Fuchs indication for primary EK (%)	Cause of re-DSAEK	Ocular comorbidities (%)	Time between primary DSAEK and re-DSAEK (mo)	F-U time after repeat DSAEK (mo)	CDVA before re-DSAEK	Mean preoperative CCT (μm)	CDVA after re-DSAEK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Gorovoy et al[61]	*Cornea* (Feb/2008)	2	59.5 ± 9.5	100%	Rej (50%)/late endothelial failure (50%)	50%	20 ± 7	6	0.80 ± 0.20 logMAR	Patient 2=875μm	0.20 ± 0.10 logMAR	100%	N/R	Patient 2 = 625 μm	0%	50%	0%	No signs of interface scarring after failed graft removal
Lee et al[62]	*Cornea* (Jun/2009)	5	68.4 ± 6.6	40%	Dislocated graft (40%)/iatrogenic PGF (60%)	60%	3.2 ± 2.7	7.6 ± 3.7	N/R	N/R	0.85 ± 0.62 logMAR	20%	N/R	638.5 ± 31.4 μm	0%	0%	20%	One patient experienced primary graft failure
Letko et al[63]	*Ophthalmology* (Feb/2011)	37	69.0 ± 12.0	86%	Unsatisfactory visual outcome (76%)/endothelial decompensation (24%)	24.3%	11/13	N/R	Snellen 20/60/ counting fingers	809/787	Snellen 20/30/ Snellen 20/60	82%	N/R	678/666	N/R	N/R	N/R	Improved visual acuity in 97% of eyes
Kim et al[64]	*Cornea* (Oct/2012)	20	69.9 ± 11.9	55%	PGF (40%)/Rej (20%)/ endothelial failure (40%)	15%	13.1 ± 10.3	27.0 ± 13.4	1.76 ± 0.62 logMAR	N/R	0.50 ± 0.41 logMAR	59%	47.3% (final F-U)	N/R	5%	0%	0%	IOP change non-significant; in eyes without comorbidities, mean CDVA improved to 0.37 logMAR
Ghosh et al[65]	*Clin Ophthalmol* (May/2013)	1	77	100%	Epithelial ingrowth	Dry AMD	22	18	1.0 logMAR	N/R	0.10 logMAR	100%	N/R	N/R	0%	0%	0%	Careful stripping and cleaning of the interface to remove any epithelial cells in cases of epithelial ingrowth after DSEK in warranted
Nahum et al[66]	*Cornea* (May/2016)	51	69.6 ± 13.1	39.1%	Rej (29.4%)/EC exhaustion (68.6%)/interface abnormalities (1.9%)	31.3%	26.4 ± 22.8	21.2 ± 17.4	1.38 ± 0.60 logMAR	N/R	0.34 ± 0.49 logMAR	N/R	44% ± 21% (2-y F-U)	N/R	0%	0%	9.8%	Visual outcomes between re-DSAEK and primary DSAEK were similar

Continued next page

TABLE 1. (Continued)

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Fuchs indication for primary EK (%)	Cause of re-DSAEK	Ocular comorbidities (%)	Time between primary DSAEK and re-DSAEK (mo)	F-U time after repeat DSAEK (mos)	CDVA before re-DSAEK	Mean preoperative CCT (μm)	CDVA after re-DSAEK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Dickman et al[67]	*Am J Ophthalmol* (Sep/2018)	103	70 ± 9	42%	PGF (25%)/endothelial failure (50%)/Rej (17%)/others (9%)	N/R	N/R	24	1.46 ± 0.10 logMAR	N/R	0.57 ± 0.09 logMAR	N/R	N/R	N/R	N/R	N/R	9% at 2y	81% cumulative probability of 5-y regraft survival
Thompson et al[68]	*Cornea* (Feb/2019)	121	70 ± 12	33%	PGF (30.6%)/ Rej (5.6%)/ late endothelial failure (58%)/ others (5.8%)	Glaucoma (36%)	23.2 ± 22.3	12	1.54 ± 0.79 logMAR	673 ± 117	0.65 ± 0.62 logMAR	N/R	36.7% (6-mo F-U)	N/R	15%	N/R	N/R	Higher preoperative IOP was predictive of greater improvement in CDVA after re-DSEK; glaucoma and previous PKP were not predictive of visual outcomes
Matsumoto et al[69]	*JCRS Online Case Reports* (Oct/2019)	1	55	0%	Late endothelial failure (100%)	Phakic IOL (100%)	24	6	2.0 logMAR	N/R	0.0 logMAR	100%	N/R	614 μm	0%	0%	0%	Repeat DSAEK was performed in combination with phakic IOL explantation and cataract surgery
Kaur et al[70]	*Indian J Ophthalmol* (Oct/2019)	62	52.6 ± 17.1	29%	PGF (55%)/Rej (16%)/endothelial failure (29%)	25.8%	8 (range, 0.15–19)	12	N/R	732.8 ± 82.5	0.44 ± 0.25 logMAR	N/R	N/R	688.3 ± 110.9	N/R	N/R	13%	87% of eyes with clear grafts at postoperative y 1

AMD, age-related macular degeneration; CCT, corneal central thickness; CDVA, corrected distance visual acuity; DSAEK, Descemet stripping automated endothelial keratoplasty; DSEK, Descemet stripping endothelial keratoplasty; EC, endothelial cell; %ECL, endothelial cell loss rate; EK, endothelial keratoplasty; F-U, follow-up time; IOL, intraocular lens; IOP, intraocular pressure; N/R, not reported; PGF, primary graft failure; PKP, penetrating keratoplasty; re-DSAEK, repeat DSAEK; re-DSEK, repeat DSEK; Rej, rejection.

ranging from 12 to 27 mo).[64,66,67] Only 1 study compared %ECL between primary DSEK and re-DSEK eyes and found no statistically significant differences.[66] However, 1 study suggests that their re-DSEK cohort had accelerated %ECL compared with their previously published data on primary DSEK eyes.[64]

Rebubbling rates were reported in 5 studies and ranged from 0% to 15%. [61,64-66,68] Immune rejection episodes were reported in 4 studies (n = 54 eyes),[61,64-66] and only occurred in 1 study (1 eye, 1.9%), which required continued topical steroid therapy for recurrent keratic precipitates.[61] Regraft failure rates were reported in 8 studies (n = 245 eyes), ranging from 0% to 20% (follow-up times ranging from 6 to 27 mo).[61,64-67,70] A prospective long-term analysis performed by the Netherlands Organ Transplantation Registry found that regraft survival is lower compared with primary graft survival.[67] These findings are similar to those reported in a retrospective study in which re-DSEK grafts were reported to be at increased risk of rejection and graft failure compared with primary DSEK eyes (Moura-Coelho et al, personal communication, 2019).

Repeat DMEK

Eight publications (n = 130 eyes) analyzed the outcomes of repeat DMEK (re-DMEK) for failed primary DMEK graft (Table 2).[55,80-86] Excluding the case report by Alió del Barrio et al,[84] primary DMEK was performed for Fuchs endothelial corneal dystrophy in 78.6%–100% of cases. Histopathological analysis of failed primary DMEK grafts has shown that the majority of failed primary DMEK grafts have subclinical, preoperative corneal endothelial dysfunction and that most cases have an abnormal fibrillary posterior collagenous layer.[81,87] DMEK failure may be associated with innate immune activation and increased cytokine levels in the aqueous humor, particularly interleukins 5 and 8.[86]

Regrafting has rendered a surgically feasible approach in cases of failed primary DMEK. Compared with primary DMEK, certain particularities in the operative protocol must be considered in re-DMEK.[55,82] The previous 3.0-mm corneal tunnel incision is reopened, the failed DMEK graft is disinserted from the host stroma using a reverse Sinskey hook under air, and the graft is removed with a DMEK forceps.[55] At this stage, careful removal of graft remnants by scraping can be performed while avoiding damage to the host posterior stroma[55,82]; injecting trypan blue into the AC may aid in visualizing DM remnants.[82] Donor Descemet roll preparation, insertion, positioning, and tamponade into the host posterior stroma are performed as for primary DMEK surgery; 20% SF6 may be used as tamponade, leaving a relatively soft eye at the end of the surgery.[55] Particularly in cases when re-DMEK is performed to manage GD, leaving the host AC completely filled with air for 60–120 min can help in reducing the risk of detachment occurring in the same quadrants, and then air-liquid exchange is performed to leave a 30%–50% air bubble.[82] It has been reported anecdotally that a second DMEK graft without removal of the failed DMEK graft effectively restored corneal transparency and vision in a case of pseudophakic bullous keratopathy.[84] Reported postoperative medication regimens are usually the same as for primary DMEK surgery.[55,82,83] We routinely prescribe topical tobramycin 0.3% and dexamethasone 0.1% eye drops every 2 h in the first postoperative day, then 6 times a day for the first postoperative week, then 4 times a day for 4 wk, and then tapering the topical steroids over the following 3 mo; topical dexamethasone 0.05% and chloramphenicol 1% ointment at bedtime for 12 wk and then at bedtime 3 times weekly until the sixth postoperative month, with discontinuation in the absence of any inflammatory signs or symptoms of rejection; and topical ocular hypotensive medications over 3 mo. In addition, we prescribe oral methylprednisolone 40 mg/d for 3 d, followed by tapering over the first 3 postoperative wk.[55]

Mean/median follow-up periods after re-DMEK ranged from 3.3 to 18 mo (range, 3–89 mo).[55,79-83,85,86] Reported mean final CDVA following re-DMEK ranged from 0.33 to 0.09 logMAR (Snellen equivalent 20/25–20/43). Five studies (n = 105 eyes) reported the proportion of eyes reaching higher CDVA at final observation[55,81-84]: 82%–100% of eyes reached CDVA ≥20/40, and 13.3%–81% of eyes reached CDVA ≥20/25. Three of these studies (n = 86 eyes) additionally reported that 18.2%–61% of eyes reached final CDVA ≥20/20.[55,82,83] The changes in corneal pachymetry were reported in 6 studies (n = 110 eyes).[81-86] Mean central corneal thickness before re-DMEK ranged from 631 to 931 μm and decreased to 512–576 μm at 6- to 12-mo follow-up after re-DMEK.

All studies except the case report by Alió del Barrio et al[84] reported comparative analyses between primary and re-DMEK eyes (n = 129 re-DMEK eyes): 1 study (n = 6 eyes) compared the preoperative and postoperative CDVA after the first and the second DMEK grafts[80]; 2 studies compared re-DMEK eyes with the subgroup of patients with successful fellow-eye primary grafts (n = 38 eyes)[81,83]; and 4 were retrospective, comparative case series (n = 50 eyes).[55,82,85,86] Five studies (n = 68 eyes) reported that visual outcomes were comparable between primary and re-DMEK eyes,[55,80,83,85] including the percentage of eyes that reached higher levels of CDVA at 1-y comparisons.[55,83] However, 2 studies reported inferior visual outcomes after re-DMEK compared with primary DMEK.[81,82] The time between graft failure and regrafting may influence visual outcomes, because average intervals between PGF or GD and regrafting ranged from 9 d and 2.9 mo in the series reporting comparable visual outcomes,[55,80,83] contrasting with the 2 studies reporting inferior visual outcomes, in which average times ranged from 146 d to 16 mo.[81,82] Prompt regrafting minimizes the duration of host corneal decompensation and associated stromal changes,[82,83,85] which can lead to increased backscatter.[60]

Mean %ECL following re-DMEK was reported in 6 studies (n = 123 eyes),[55,81-83,85] ranging from 29.8% to 49.5% at 6-mo follow-up,[82,83,85,86] from 34% to 49.8% at 12-mo follow-up,[81,83,86] and 48.2% in eyes with medium-term follow-up.[55] Six studies (n = 111 eyes) reported rebubbling rates following re-DMEK, ranging from 5.9% to 33% after excluding the case report by Alió del Barrio et al.[55,80,82,83,85,86] Eyes that had GD after primary DMEK may be at increased risk of rebubbling after re-DMEK,[55,82] which suggests that host intrinsic properties may interfere with graft adherence. Four studies (n = 104 eyes) reported rejection rates,[55,81-85] ranging from 0% to 14.3%.[55,81-83] In the studies reporting eyes with immune rejection episodes in the regraft, 1 eye of each cohort had undergone

TABLE 2.

Outcomes of repeat DMEK

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Fuchs indication for primary EK (%)	Cause of re-DMEK	Ocular comorbidities (%)	Time between primary DMEK and re-DMEK (mo)	F-U time after re-DMEK (mo)	CDVA before re-DMEK	Mean preoperative CCT (μm)	CDVA after re-DMEK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Yoeruek et al[80]	*Cornea* (Nov/2013)	6	66.8 ± 5.6	100%	Failed primary DMEK (unspecified)	0%	2.9 ± 1.5	3.3 ± 1.7	1.50 ± 0.28 logMAR	N/R	0.13 ± 0.05 logMAR	N/R	N/R	N/R	33.3%	N/R	0%	Visual outcomes and types of complications and their incidence were comparable with the first surgery
Cirkovic et al[81]	*Cornea* (Jan/2015)	18	69.0 ± 7.0	83.3%	Failed primary DMEK (78%)/graft detachment not resolved by rebubbling (22%)	17%	4.9	12	1.90 logMAR	807 ± 160	0.3 logMAR	86.7%	45% ± 11% (12-mo F-U)	576 ± 178	0.5 ± 0.9 rebubbling procedures	0%	5.6%	Telephone interviews indicative of a very strong recommendation for repeat DMEK
Baydoun et al[82]	*Ophthalmology* (Jan/2015)	17	69 ± 14	88.2%	Graft detachment (82%)/EC exhaustion (12%)/Rej (6%)	0%	16 ± 9	12	N/R	703 ± 26	86% CDVA ≥20/40, and 57% CDVA ≥20/25	86%	49.8% (12-mo F-U)	515 ± 39	5.9%	5.9%	17.6%	Increased %ECL and lower % eyes with CDVA ≥20/25 compared with primary DMEK eyes
Price et al[83]	*Ophthalmology* (Aug/2015)	55	69 (range, 42–89)	93%	Surgical complications (38%)/PGF (40%)/EC exhaustion (9%)/other causes (13%)	11%	21 d in surgical complications/32 d in PGF/27 mo in EC exhaustion	18 (range, 3–61)	N/R	631 ± 81	20/25 Snellen	100%	31 ± 14% (12-mo F-U)	512 ± 40	13%	0%	2%	Re-DMEK eyes had similar %ECL and visual outcomes compared with fellow primary DMEK eyes
Alió del Barrio et al[84]	*Cornea* (Jun/2018)	1	72	0%	Rej (100%)	100%	18	6	0.70 logMAR	691 μm	0.25 logMAR	100%	N/R	529 μm	0%	0%	0%	Repeat DMEK was successful without primary DMEK graft removal (DMEK under failed DMEK)

Continued next page

TABLE 2. (Continued)

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Fuchs indication for primary EK (%)	Cause of re-DMEK	Ocular comorbidities (%)	Time between primary DMEK and re-DMEK (mo)	F-U time after re-DMEK (mo)	CDVA before re-DMEK	Mean preoperative CCT (μm)	CDVA after re-DMEK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Agha et al[85]	*Clin Ophthalmol* (Mar/2019)	13	73.2 ± 7.6	84.6%	Failed primary DMEK (unspecified)	23.1%	12.5 ± 6.0	6	1.96 ± 0.99 logMAR	929 ± 217	0.33 ± 0.20 logMAR	N/R	30.1% (6-mo F-U)	519 ± 43	23.1%	0%	0%	Functional and anatomical outcomes were similar between re-DMEK and primary DMEK eyes
Luznik et al[86]	*Ophthalmology* (Oct/2019)	6	72 ±11	83.3%	Failed primary DMEK (unspecified)	N/R	18.5	12	1.50 (range, 0.4–2.0) logMAR	931 ± 245 μm	0.3 (range, –0.2 to 0.8) logMAR	N/R	49.0 ± 8.8% (12-mo F-U)	524 μm	16.7%	0%	16.7% (PGF)	Increased complication rates and levels of cytokines in the aqueous humor compared with primary DMEK eyes,
Moura-Coelho et al[55]	*Am J Ophthalmol* (Mar/2020)	14	68.4 ± 9.0	78.6%	PGF (57%)/EC exhaustion (29%)/Rej (14%)	35.7%	Eyes with PGF within 30 d; eyes with late graft failure 30.8 ± 20.4 mo	14.5 (range, 6–89)	1.30 ± 0.65 logMAR	N/R	0.09 ± 0.26 logMAR	81.8%	48.2 ± 15.1% (final F-U)	N/R	28.6%	14.3%	21.4%	Re-DMEK eyes had similar visual outcomes, %ECL and rejection rate compared with successful primary DMEK eyes, but high % graft failure after re-DMEK

CCT, central corneal thickness; CDVA, corrected distance visual acuity; DMEK, Descemet membrane EK; EC, endothelial cell; %ECL, endothelial cell loss rate; EK, endothelial keratoplasty; F-U, follow-up time; N/R, not reported; PGF, primary graft failure; re-DMEK, repeat DMEK; Rej, rejection.

re-DMEK for rejection of the primary graft.[53,82] All studies reported regraft failure rates, ranging from 0% to 21.4% (with follow-up times ranging between 3 and 89 mo). Five studies (n = 110 eyes) reported other complications after re-DMEK,[55,81-83,86] including cataract or IOL opacification (n = 4),[55,81,82,86] IOP spikes or glaucoma progression requiring additional medication or surgery (n = 16),[55,82,83,86] macular edema (n = 3),[55,86] pupillary block (n = 1),[55] and corneal ulcer (n = 1).[82]

Secondary DMEK for Eyes With Previous DSEK Grafts

Six publications reported the outcomes of secondary DMEK for eyes with previous DSEK grafts (n = 79; Table 3).[74,88-92] Early reintervention should be considered because fibrotic processes might be anticipated in this setting.[74] DSEK grafts are carefully mobilized using a reverse Sinskey hook or blunt spatula and then explanted. In this setting, adjacent remnants of host DM have been found to be present at the donor-to-host stromal interface in as many as 50% of eyes and, in most cases, in the visual axis.[89] Meticulous search for adjacent remnants of host DM and tags of stroma should thus be performed[91]; these can be removed using a reverse Sinskey hook or a corneal scraper under air after trypan blue staining.[92] Graft tamponade into the recipient's stroma can be made using air or 20% SF6. Proposed techniques to improve the visibility of the AC include the mechanical removal of the edematous corneal epithelium, application of methylcellulose on the corneal surface during surgery, and optimal illumination.[90]

The optical quality of the transplanted cornea can be fully restored by careful removal of the DSEK graft and implantation of a DMEK graft,[88,90] and therefore, DMEK for eyes with poor visual performance after DSEK has gained increasing interest among corneal surgeons. Mean CDVA improved significantly following secondary EK in all studies (n = 79 eyes) over mean follow-up times ranging from 6 to 18 mo (mean preoperative CDVA ranged from 0.50 to 1.72 logMAR, and mean final CDVA ranged from 0.06 to 0.51 logMAR). Two studies (n = 15) reported that 91.7%–100% of eyes reached CDVA ≥20/40 and CDVA ≥20/25 at 6-mo follow-up[88,89]; in these 2 studies, 33%–42% of eyes reached final CDVA ≥20/20.[88,89] Only 1 study compared outcomes between primary DMEK and secondary DMEK after primary DSEK (n = 8)[74] and reported the inferior outcomes in the latter group. Fibrotic changes in the host cornea due to persistent corneal edema after graft failure and suboptimal status of the DM-stromal interface may account for inferior outcomes.[74]

Three studies (n = 56 eyes) reported the rate of CEC loss, with mean %ECL ranging from 34.7% to 43.7% over 6- to 18-mo follow-up periods.[90-92] This outcome is comparable with reported %ECL following primary DMEK.[8] Four studies (n = 59 eyes) reported rebubbling rates, ranging from 0% to 20%.[88,90-92] Four studies (n = 59 eyes) reported rejection rates in this setting, ranging from 0% to 3.8%[87,90-92]; only 1 study documented cases of immune rejection episode (1 eye), which ended in graft failure.[91] All 6 studies reported graft failure rates, ranging from 0% to 19.2% (mean follow-up times ranging from 6 to 18 mo).[74,88-92]

Secondary DSEK for Eyes With Failed Primary DMEK Grafts

Three studies (n = 39 eyes) have analyzed the outcomes of secondary DSEK in cases of failed primary DMEK (Table 4).[93-95] Two studies (n = 18 eyes) used "conventional" DSEK grafts (one using manual preparation of the graft and another one using DSAEK),[93,94] and 1 study (n = 21 eyes) used UT-DSAEK.[95] This approach may be particularly useful during the learning curve of DMEK surgery,[94,95] as well as in some cases, in which significant corneal edema hinders a good visualization of the AC.[93] In the secondary surgery, the 3.0-mm corneal incision fashioned for the primary DMEK is reopened, the primary graft is stained by injecting trypan blue 0.06% into the AC, and then the failed graft is disinserted from the host using a reverse Price-Sinskey hook and removed from the eye using an intraocular forceps. The host posterior stromal bed should be checked for irregularities under air and the AC thoroughly irrigated to remove all remnant graft tissue.[93] The DSEK graft is then inserted through the corneal incision, unfolded, and positioned onto the recipient posterior stroma; all 3 studies used air filling of the AC, leaving a 50% air-filled AC at the end of the surgery.[93-95]

All 3 studies found an improvement in mean CDVA after secondary EK. After excluding eyes with comorbidities (6 eyes in 2 studies), mean final CDVA improved from 0.69–1.52 to 0.06–0.40 logMAR at 6- to 12-mo follow-up analyses.[93-95] The percentages of eyes reaching CDVA ≥20/40, ≥20/25, and ≥20/20 ranged from 62% to 100%, 0% to 92%, and 0% to 31%, respectively.[93-95] The study of UT-DSAEK for failed DMEK reported better visual outcomes than those of conventional DSEK/DSAEK. In eyes undergoing conventional DSEK/DSAEK for failed DMEK, 62%–87% reached CDVA ≥20/40, and only 1 case in both studies reached CDVA ≥20/25 (range, 0%–13%)[93,94]; in contrast, in the study by Graffi et al,[95] 92% of eyes undergoing UT-DSAEK for failed DMEK reached CDVA ≥20/25, and 30% reached CDVA ≥20/20. These differences likely reflect the influence of graft thickness and regularity of the donor graft on visual performance following DSEK, although the role of the learning curve and experience in DMEK surgery may also play a role in these outcomes because DSEK publications antedated that of UT-DSAEK by 5–8 y. One study found an increase in central corneal light scattering after secondary DSAEK performed after a failed DMEK compared with primary DSAEK eyes.[94]

Two studies (n = 31 eyes) reported CEC loss rates 12 mo after secondary DSEK after failed primary DMEK, ranging between 38% and 46.4%.[93,95] The differences between manually prepared DSEK and UT-DSAEK were not statistically significant (mean difference = 7.2%; $P = 0.531$). Two studies (n = 31 eyes) reported rebubbling rates ranging from 0% to 30%, in favor of UT-DSAEK.[93-95] Only 1 study (n = 21 eyes) reported outcomes regarding allograft rejection episodes after secondary EK in this setting and found no cases of rejection episodes in the first postoperative year.[95] None of the 3 studies reported cases of failed regraft. Only 1 study (n = 21 eyes) reported other complications after secondary EK,[95] with a 23.8% complication rate (graft wrinkling, 1 eye; and IOL opacification in 4 eyes, 2 of which required IOL exchange).[95]

TABLE 3.

Outcomes of secondary DMEK following primary DSEK

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Secondary EK	Fuchs indication for primary EK (%)	Ocular comorbidities (%)	Time between primary and secondary EK (mo)	F-U time after secondary EK (mo)	CDVA before secondary EK	Mean preoperative CCT (μm)	CDVA after secondary EK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Ham et al[88]	*Cornea* (Nov/2010)	3	53.0±10.7	DMEK for poor visual outcome following DSEK	100%	0%	20.0±4.3	6	0.50±0.31 logMAR	620.7±37.5	0.07±0.05 logMAR	100%	N/R	509.7±18.8	0%	0%	0%	Functional results after secondary DMEK for poor visual outcome of primary graft comparable to primary DMEK
Dirisamer et al[89]	*Acta Ophthalmologica* (Mar/2013)	12	66±13	DMEK for poor visual outcome following DSEK	91.7%	25%	32±17	6	0.57±0.38 logMAR	670±112	0.06±0.12 logMAR	91.7%	Final ECD 1709±461 cells/mm^2	517±57	N/R	N/R	0%	Secondary DMEK allows complete visual recovery in eyes with poor visual outcomes after primary DSEK
Brockmann et al[74]	*JAMA Ophthalmol* (Jul/2015)	8	79.4±7.2	DMEK for graft failure following DSEK	N/R	25%	21.4±17.8	12	1.13±0.50 logMAR	900±209	0.38±0.36 logMAR	N/R	Final ECD 908±143 cells/mm^2	524±27	N/R	N/R	0%	Functional results after secondary DMEK for graft failure inferior to primary DMEK
Weller et al[90]	*Am J Ophthalmol* (Jun/2015)	15	67.3±10.2	DMEK for graft failure following DSEK	93%	0%	26±17	18	1.27±0.34 logMAR	917±184	0.14±0.14 logMAR	N/R	43.7% (18-mo F-U)	506±66	13.3%	0%	0%	DMEK showed surgical feasibility in eyes with failed DSEK, with good adhesion of the graft and good optical quality

Continued next page

TABLE 3. (Continued)

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Secondary EK	Fuchs indication for primary EK (%)	Ocular comorbidities (%)	Time between primary and secondary EK (mo)	F-U time after secondary EK (mo)	CDVA before secondary EK	Mean preoperative CCT (μm)	CDVA after secondary EK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Sorkin et al[91]	*Cornea* (Jun/2018)	26	71.9 ± 12.6	DMEK after primary DSAEK (failed graft 70% or suboptimal visual outcome 30%)	57%	50%	8.5 ± 13.0	15.1 ± 10.6	0.84 ± 0.50 logMAR	N/R	0.51 ± 0.49 logMAR	N/R	39.7 ± 22.3% (6-mo F-U)	N/R	11.5%	3.8%	19.2%	Search for remnant islands and tags of stroma in the host interface area should be meticulous after removing the old DSEK graft
Agha et al[92]	*Clin Ophthalmol* (Mar/2019)	15	73.6 ± 7.6	DMEK for graft failure following DSEK	80%	N/R	15 ± 8	12	1.72 ± 0.62 logMAR	869.0 ± 209.9	0.23 ± 0.24 logMAR	N/R	34.7% (12-mo F-U)	511.7 ± 67.7	20%	0%	6.7%	Visual acuity and optical quality were effectively improved even in patients with longstanding corneal decompensation

CCT, central corneal thickness; CDVA, corrected distance visual acuity; DMEK, Descemet membrane endothelial keratoplasty; DSAEK, Descemet stripping automated endothelial keratoplasty; DSEK, Descemet stripping endothelial keratoplasty; ECD, endothelial cell density; %ECL, endothelial cell loss rate; EK, endothelial keratoplasty; F-U, follow-up time; N/R, not reported.

TABLE 4.

Secondary DSEK for failed primary DMEK graft

Author	Journal (mo/y)	Eyes (n)	Patient age (y)	Secondary EK	Fuchs indication for primary EK (%)	Ocular comorbidities (%)	Time between primary and secondary EK (mo)	Follow-up time after secondary EK (mo)	CDVA before secondary EK	Mean pre-operative CCT (μm)	CDVA after secondary EK	% Eyes reaching CDVA ≥20/40	%ECL	Mean final CCT (μm)	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Dapena et al[93]	*Br J Ophthalmol* (Feb/2010)	10	67.6 ± 12.0	DSAEK for failed primary DMEK (primary graft failure)	100%	20%	0.8 ± 0.2 (2–5 wk)	12	0.69 ± 0.41 logMAR	N/R	0.40 ± 0.23 logMAR	70% (87% after excluding eyes with comorbidities)	46.4% (12-mo F-U)	N/R	30%	N/R	0%	Secondary DSEK after failed primary DMEK may yield similar clinical outcomes compared with primary DSEK.
Arnalich-Montiel et al[94]	*Graefes Arch Clin Exp Ophthalmol* (Nov/2013)	8	62.1 ± 8.2	DSAEK for failed primary DMEK	100%	0%	1.7 ± 0.8	6	0.65 ± 0.22 logMAR	N/R	0.24 logMAR (range, 0.13–0.52)	62%	N/R	N/R	N/R	N/R	0%	Increased corneal scattering after secondary DSAEK following primary DMEK compared with primary DSAEK eyes, which has a negative impact on visual acuity.
Graffi et al[95]	*Br J Ophthalmol* (May/2018)	21	69.2 ± 7.2	UT-DSAEK for failed primary DMEK	85.7%	19%	3.0 ± 2.1	12	1.52 ± 0.57 logMAR	N/R	0.06 ± 0.05 logMAR (after excluding eyes with comorbidities)	100%	38.9% (12-mo F-U)	N/R	0%	0%	0%	Complication rate 23.8%.

CCT, central corneal thickness; CDVA, corrected distance visual acuity; DMEK, Descemet membrane endothelial keratoplasty; DSAEK, Descemet stripping automated endothelial keratoplasty; DSEK, Descemet stripping endothelial keratoplasty; %ECL, endothelial cell loss rate; EK, endothelial keratoplasty; F-U, follow-up time; N/R, not reported; UT-DSAEK, ultrathin DSAEK.

Postoperative Care and Optimization of Graft Survival

As mentioned earlier, EK grafts are considered low risk for immune rejection episodes. Typical postoperative regimens to reduce the risk of allograft rejection episodes after primary EK include topical corticosteroid therapy with tapering over 6–12 mo.[31,38,41] Our immune rejection prophylaxis regimen after EK includes tobramycin 0.3% and dexamethasone 0.1% eye drops every 2 h in the first postoperative day, then 6 times a day for the first postoperative week, then 4 times a day for 4 wk, and then tapering the topical steroids over the following 3 mo, plus dexamethasone 0.05% and chloramphenicol 1% ointment at bedtime for 12 wk, and then at bedtime 3 times weekly until the sixth postoperative month.[19] In addition, we also include oral methylprednisolone 40 mg daily for 3 d, then 20 mg daily from postoperative day 4 to 6, then 10 mg daily during the second postoperative week, and then 10 mg every 48 h during the third postoperative week. We also include topical timolol eye drops twice daily for 3 mo and oral acetazolamide in the first postoperative day to prevent IOP spikes and corticoid-responsive IOP elevations. However, recent evidence suggests that continued use of a topical corticosteroid may be protective against rejection episodes after the first postoperative year following DMEK.[41,96] The reported postoperative rejection prophylaxis protocols after secondary EK are usually the same as for primary EK.[55,82,83] In contrast, repeat PKP is considered a high-risk keratoplasty scenario, and in addition to continuing topical corticosteroids indefinitely, many corneal surgeons also advocate the use of systemic immunosuppressants to reduce the risk of allograft rejection; these include systemic corticosteroids, mycophenolate mofetil, cyclosporine A, rapamycin, and tacrolimus.[46,97] However, the evidence for the effects of immunosuppressants is limited at present.[46,98]

Fourteen studies (n = 275 eyes) reported rejection rates (excluding single-patient case reports). Five eyes had allograft rejection episodes (average rejection rate = 1.8%; range, 0%–50%), which is comparable with the mean 1.9% rejection rate following primary DMEK reported by the American Academy of Ophthalmology.[8] One case of re-DMEK rejection had previous history of immune rejection of the primary DMEK graft,[82] and 1 case of re-DMEK rejection occurred in an eye with previously rejected DMEK graft performed for failed PKP.[55] Three of the 5 regrafts with rejection episodes eventually failed (2 re-DMEK eyes and 1 DMEK for failed primary DSEK graft).[55,91] One retrospective study of repeat DSEK eyes found that these eyes may have a higher risk of allograft rejection compared with primary DSEK (Moura-Coelho et al, personal communication, 2019). These findings raise the question as to whether secondary EK eyes (as well as eyes undergoing EK for failed PKP) graft may be at a higher risk of graft rejection and rejection-related graft failure, compared with the low risk of rejection-related graft failure of primary EK eyes. An aggressive steroid regimen may be needed in the postoperative period, at least in the subset of patients undergoing repeat keratoplasty for graft rejection.[54,78] In these cases, a longer duration or indefinite period of topical corticosteroid prophylaxis could be considered, with careful attention to IOP rises or development or progression of glaucoma.[38] Interestingly, Alió del Barrio et al[84] have suggested adding oral steroids for 1 mo plus topical tacrolimus 0.03% and systemic tacrolimus 1 mg every 12 h in a case of repeat DMEK for primary DMEK failure due to allograft rejection, and the regraft did not experience rejection episodes.

A potential cause of increased %ECL and graft failure after DSEK and DMEK is viral infection caused by herpes simplex virus (HSV) or cytomegalovirus (CMV). When considering retransplantation in a failed corneal graft, the clinician should maintain a high index of suspicion for CMV and HSV infection as potential causes of graft failure.[99] HSV-1 antigen immunoreactivity has been detected in 2%–14% of failed DSEK grafts,[7,100] and HSV endotheliitis should be kept in mind in the early postoperative period after DMEK.[101] CMV endotheliitis after corneal transplantation is an increasingly recognized complication and may be at least as common as graft rejection in Asia,[99] although this has not been confirmed in a study conducted in the United Kingdom.[102] Viral endotheliitis post-EK can closely resemble EK graft rejection with keratic precipitates and mild anterior uveitis, and it is important to differentiate endotheliitis from rejection because the immunosuppressive treatment for rejection episodes can exacerbate the infection. This diagnosis should be suspected in eyes with presumed episodes of allograft rejection unresponsive to steroids, in eyes with hypertensive anterior uveitis, and in eyes with unexplained EC loss in relatively quiet eyes.[103] Viral endotheliitis tends to occur earlier postoperatively usually within the first postoperative year compared with immune rejection episodes.[104] Clinical findings for eyes with AC inflammation after keratoplasty may be indicative of the cause of the inflammation, and IOP elevation may mirror the activity of the endotheliitis in cases of HSV and CMV endotheliitis.[105] A relatively low threshold for aqueous paracentesis and CMV-DNA and HSV-DNA polymerase chain reaction (PCR) analysis have been proposed by some authors,[99] who perform aqueous PCR to exclude viral endotheliitis before treating for immune rejection.[104]

With expanding indications for EK in recent years, there is a growing experience with EK for the indication of corneal decompensation secondary to HSV or CMV endotheliitis. In eyes with HSV-related corneal endothelial failure, DMEK leads to improvement in CDVA, although visual recovery is limited compared with DMEK for other causes.[106] Importantly, these eyes have a higher rate of postoperative complications, including PGF and recurrence of endotheliitis in 12% and 29% of eyes, respectively.[106] One study has found promising outcomes of DMEK in this setting; the disease should be quiescent for ≥6 mo before surgery, that PCR for HSV be performed and be negative 10 d before surgery, and that intensive, perioperative prophylactic oral antiviral and topical antiviral therapy should be continued for at least 1 y to prevent recurrence.[107] Some corneal surgeons suggest keeping topical antivirals indefinitely to reduce the risk of recurrence and subsequent graft failure in eyes undergoing EK for HSV-related endotheliitis.[108]

In the setting of EK for CMV-related corneal endothelial failure, the management of post-EK recurrent endotheliitis is challenging for corneal specialists. In one study, all the patients with detectable CMV-DNA in the aqueous at the time of keratoplasty developed CMV endotheliitis postkeratoplasty and experienced graft failure.[109] Moreover, one

study found that patients diagnosed with CMV endotheliitis before EK are more likely to have recurrent endotheliitis within the first postkeratoplasty year, even when preoperative anti-CMV treatment and confirmed eradication of CMV and ocular inflammation before keratoplasty were performed.[104] Early recognition and effective treatment are therefore indicated to optimize graft survival following EK in this setting.[110] Optimizing IOP and ensuring quiescence of intraocular inflammation before transplantation is advocated. Preoperative aqueous PCR analysis for CMV-DNA has been recommended before corneal transplantation by some authors.[110] In their center, CMV-positive patients should undergo a systemic and topical antiviral treatment and only after repeat PCR becomes negative in EK performed; postoperatively, the patient is kept on prophylactic systemic oral antiviral therapy for 3 wk and on long-term topical ganciclovir therapy, and a repeat aqueous CMV-DNA PCR analysis is performed to ensure no recurrence of infection.[110] Long-term topical ganciclovir may prevent recurrence of CMV-associated graft failure after EK.[111] Notably, no optimal treatment regime for CMV corneal endotheliitis has been established to date. Intravenous ganciclovir and oral valganciclovir have shown comparable efficacy for CMV disease in solid organ recipients,[112] and this has been extrapolated for keratoplasty by corneal surgeons. Cessation of treatment of CMV endotheliitis has been based on clinical response, with a conservative goal of maintaining 3 mo of antiviral therapy after clinical resolution coupled with a negative aqueous CMV-DNA analysis.[99]

DISCUSSION

Our study provides good evidence that secondary EK renders surgical feasibility and significant improvement in visual acuity and has a good safety profile. Table 5 summarizes the main functional and anatomical outcomes for each scenario in secondary corneal endothelial transplantation. Although both secondary DSEK and secondary DMEK produce significant functional improvement with comparable safety profiles, the findings in this review suggest that eyes undergoing secondary DMEK or secondary UT-DSAEK *may be* more likely to reach higher levels of visual acuity compared with eyes undergoing secondary DSEK (Table 5). However, the quality of this evidence is low, as few publications have reported the proportions of eyes with higher levels of visual acuity. We consider that reporting the proportion of eyes reaching CDVA ≥20/40, ≥20/25, and ≥20/20 should be made a standard of quality in future studies of EK (both primary and subsequent grafts) and that further studies are needed to ascertain whether visual outcomes after secondary DSEK are comparable with those of secondary DMEK.

The visual outcomes following primary and secondary EK in the setting of corneal endothelial failure have been consistently superior to those of repeat PKP. Although repeat PKP produces significant visual improvement, visual outcomes are decreased in eyes undergoing multiple regrafts, with a lower proportion of eyes achieving higher levels of visual acuity.[42,45,46,113,114] Importantly, PKP may also be considered in some cases of failed EK when there is significant opacification of the anterior cornea. Particular considerations in the operative protocol compared with primary EK surgery are to be taken into consideration in secondary EK. Identification and correction of potential factors influencing graft failure (eg, glaucoma, IOL, infection) should be addressed preoperatively and at the time of the surgery.

Our review has several limitations, and it highlights several knowledge gaps that warrant further research efforts concerning secondary EK. First, most available studies to date are retrospective with short follow-up times, and there is a lack of prospective studies. In addition, most studies represent relatively small case series, although this is expected given that DMEK and DSEK are recent techniques. Visual outcomes are likely comparable with those of virgin primary EK eyes, although this is not definite. A shorter interval between graft failure and regrafting likely influences positively the visual outcomes of secondary EK before fibrotic changes induced by corneal edema ensue. Complication rates following secondary EK, including the CEC loss rate, rebubbling rate, and allograft rejection rate, may also be comparable with those of primary EK, and the complication rates following secondary DSEK and secondary DMEK seem to be comparable (Table 5). However, careful preparation and manipulation of the graft is warranted in secondary EK to minimize EC loss. Likewise, meticulous removal of potential graft remnants under air must be performed to optimize the adherence of grafts, particularly in eyes in which GD occurred in the primary graft, as these eyes may be at a higher risk of detached regraft. Immune rejection protocols in secondary EK may require longer-term steroid therapy or even indefinite steroid therapy, particularly in cases of immune rejection of the primary graft.

Finally, secondary EK grafts may be at a higher risk of failure compared with primary grafts, raising the question as to whether these should be regarded as a slightly higher-risk group compared with primary EK eyes. In a large analysis of EK procedures performed in Medicare beneficiaries, 11.6% of eyes underwent repeat keratoplasty, and approximately 17% of eyes received >1 repeat graft.[56] This is in line with the notion that repeat PKP grafts are high-risk corneal transplants, and in these cases, rejection episodes occur in 30%–60% of grafts and up to 70% will fail within 10 y despite local or systemic immunosuppression.[46] It must be emphasized, however, that suboptimal surgical technique in the primary EK procedure may also contribute to increased risk of poor adherence of the secondary EK grafts. Prospective, multicenter, comparative studies are encouraged to determine whether medium- and long-term rates of EC loss and graft failure after secondary EK are comparable with primary EK. In these eyes, promoters of EC proliferation and migration, such as Rho kinase inhibitors, may have a particularly relevant role in improving graft transparency and survival.[46,115,116]

In conclusion, with the growing experience and expanding indications for corneal endothelial transplantation, surgeons dealing with EK surgery will find an increasing number of patients with failing DSEK and DMEK grafts. In these cases, secondary EK grafts provide significant visual improvement. Importantly, our literature review raises relevant questions in secondary EK surgery for which additional studies are strongly encouraged. These include (1) understanding if secondary DMEK or secondary UT-DSAEK are associated with better visual outcomes

TABLE 5.

Summary of findings regarding outcomes following secondary endothelial keratoplasty

Clinical setting	Studies (eyes, n)	F-U (mo)	CDVA after secondary EK	% Eyes reaching CDVA ≥20/40	% Eyes reaching CDVA ≥20/25	%ECL	Rebubbling rate (%)	Rejection rate (%)	Graft failure rate (%)	Comments
Repeat DSEK/DSAEK[61-70]	10 (403)	6–27	0.50–0.18 logMAR (Snellen 20/30–20/63)	20%–100%[a]	0%[b62]	36.7%–47.3% (6–27 mo F-U)	0%–15%	1 of 54 eyes (1.9%) Range, 0%–50%	0%–20%	Repeat DSEK graft survival may be lower compared with primary grafts,[65] although this is not consensual.[64]
Repeat DMEK[55,80-86]	8 (130)	3.3–14.5	0.33–0.09 logMAR (Snellen 20/25–20/43)	82%–100%	13.3%–81%	34%–49.8% (6–14.5 mo F-U)	5.9%–33%	3 of 104 eyes (2.8%) Range, 0%–14.3%	0%–21.4%	Most, but not all, studies suggest visual outcomes are comparable between primary and secondary DMEK; 18.2%–61% of eyes reached CDVA ≥20/20[55,81,82]; other reported complications: cataract and IOL opacification, IOP spikes or glaucoma progression, macular edema, pupillary block, corneal ulcer.
DMEK after failed DSEK/DSAEK graft[74,88-92]	6 (79)	6–18	0.51–0.06 logMAR (Snellen 20/23–20/65)	91.7%–100% (6-mo F-U)	91.7%–100%[88,89]	34.7–43.7% (6–18 mo F-U)	0%–20%	1 of 59 eyes (1.7%) Range, 0%–3.8%	0%–19.2%	As many as 33%–42% may reach final CDVA ≥20/20.[87,88] Visual outcomes after DMEK for failed DSEK may inferior to those of primary DMEK grafts, although this is not consensual.
DSEK/DSAEK after failed DMEK graft[93,94]	2 (18)	6–12	0.40 – 0.24 logMAR (Snellen 20/35–20/50)	62%–87%	0%–13%	46.4% (12-mo F-U)[93]	30%[93]	N/R	0%	No studies reported other complications.
UT-DSAEK after failed DMEK graft[95]	1 (21)	12	Mean 0.06 ± 0.05 logMAR (Snellen 20/25 ± 20/86)	100%	92%	38.9% (12-mo F-U)	0%	0%	0%	31% of eyes reached CDVA ≥20/20 in this study. Other complications reported: IOL opacification (2 eyes required IOL exchange).

[a]If reports with ≤2 eyes were excluded from the analysis, the proportion of eyes reaching CDVA ≥20/40 after repeat DSEK/DSAEK would be 20%–82%.[60-64,68]

[b]If reports with ≤2 eyes were excluded from the analysis, no eyes undergoing repeat DSEK reached CDVA ≥20/25.[61]

CDVA, corrected distance visual acuity; DMEK, Descemet membrane endothelial keratoplasty; DSAEK, Descemet stripping automated endothelial keratoplasty; DSEK, Descemet stripping endothelial keratoplasty; %ECL, endothelial cell loss rate; EK, endothelial keratoplasty; F-U, follow-up time; IOL, intraocular lens; IOP, intraocular pressure; N/R, not reported; UT-DSAEK, ultrathin DSAEK.

compared with the "conventional" DSEK/DSAEK techniques, and in which clinical scenarios, secondary DSEK or PKP should be considered over secondary DMEK; (2) ascertaining whether the visual outcomes of EK regrafts are comparable with those of primary EK eyes; (3) understanding whether secondary EK eyes are in fact a higher-risk subgroup in corneal transplantation compared with primary EK eyes; and (4) ascertaining whether middle- and long-term endothelial cell loss and regraft failure rates are comparable with those of primary EK.

REFERENCES

1. Güell JL, El Husseiny MA, Manero F, et al. Historical review and update of surgical treatment for corneal endothelial diseases. *Ophthalmol Ther*. 2014;3:1–15.
2. Eye Bank Association of America. 2019 Eye Banking Statistical Report. Available at https://restoresight.org/wp-content/uploads/2020/04/2019-EBAA-Stat-Report-FINAL.pdf. Accessed December 18, 2020.
3. DeMill DL, Woodward MA, Milan S, et al. Descemet membrane endothelial keratoplasty. American Academy of Ophthalmology®. EyeWiki. Published June 30, 2015. Updated September 13, 2020. Available at https://eyewiki.org/Descemet_Membrane_Endothelial_Keratoplasty. Accessed December 19, 2020.
4. Mannis MJ, Holland EJ. *Cornea*. Elsevier; 2017.
5. Stuart AJ, Romano V, Virgili G, et al. Descemet's membrane endothelial keratoplasty (DMEK) versus Descemet's stripping automated endothelial keratoplasty (DSAEK) for corneal endothelial failure. *Cochrane Database Syst Rev*. 2018;6:CD012097.
6. Williams KA, Keane MC, Coffey NE, et al. The Australian Corneal Graft Registry 2018 Report. 2018. Available at https://dspace.flinders.edu.au/xmlui/bitstream/handle/2328/37917/ACGR%202018%20Report.pdf?sequence=3&isAllowed=y. Accessed August 4, 2020.
7. Shulman J, Kropinak M, Ritterband DC, et al. Failed Descemet-stripping automated endothelial keratoplasty grafts: a clinicopathologic analysis. *Am J Ophthalmol*. 2009;148:752–759.e2.
8. Deng SX, Lee WB, Hammersmith KM, et al. Descemet membrane endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2018;125:295–310.
9. Ham L, Dapena I, Liarakos VS, et al. Midterm results of Descemet membrane endothelial keratoplasty: 4 to 7 years clinical outcome. *Am J Ophthalmol*. 2016;171:113–121.
10. Birbal RS, Ni Dhubhghaill S, Bourgonje VJA, et al. Five-year graft survival and clinical outcomes of 500 consecutive cases after Descemet membrane endothelial keratoplasty. *Cornea*. 2020;39:290–297.
11. Vasiliauskaitè I, Oellerich S, Ham L, et al. Descemet membrane endothelial keratoplasty: ten-year graft survival and clinical outcomes. *Am J Ophthalmol*. 2020;217:114–120.
12. Price MO, Fairchild KM, Price DA, et al. Descemet's stripping endothelial keratoplasty five-year graft survival and endothelial cell loss. *Ophthalmology*. 2011;118:725–729.
13. Anshu A, Price MO, Price FW. Descemet's stripping endothelial keratoplasty: long-term graft survival and risk factors for failure in eyes with preexisting glaucoma. *Ophthalmology*. 2012;119:1982–1987.
14. Ang M, Soh Y, Htoon HM, et al. Five-year graft survival comparing Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty. *Ophthalmology*. 2016;123:1646–1652.
15. Wakimasu K, Kitazawa K, Kayukawa K, et al. Five-year follow-up outcomes after Descemet's stripping automated endothelial keratoplasty: a retrospective study. *BMJ Open Ophthalmol*. 2020;5:e000354.
16. Lee WB, Jacobs DS, Musch DC, et al. Descemet's stripping endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2009;116:1818–1830.
17. Madi S, Leon P, Nahum Y, et al. Five-year outcomes of ultrathin Descemet stripping automated endothelial keratoplasty. *Cornea*. 2019;38:1192–1197.
18. Terry MA, Aldave AJ, Szczotka-Flynn LB, et al; Cornea Preservation Time Study Group. Donor, recipient, and operative factors associated with graft success in the cornea preservation time study. *Ophthalmology*. 2018;125:1700–1709.
19. Güell JL, Morral M, Gris O, et al. Comparison of sulfur hexafluoride 20% versus air tamponade in Descemet membrane endothelial keratoplasty. *Ophthalmology*. 2015;122:1757–1764.
20. Pilger D, Wilkemeyer I, Schroeter J, et al. Rebubbling in Descemet membrane endothelial keratoplasty: influence of pressure and duration of the intracameral air tamponade. *Am J Ophthalmol*. 2017;178:122–128.
21. Aldave AJ, Terry MA, Szczotka-Flynn LB, et al; Cornea Preservation Time Study Group. Effect of graft attachment status and intraocular pressure on Descemet stripping automated endothelial keratoplasty outcomes in the cornea preservation time study. *Am J Ophthalmol*. 2019;203:78–88.
22. Chaurasia S, Vaddavalli PK, Ramappa M, et al. Clinical profile of graft detachment and outcomes of rebubbling after Descemet stripping endothelial keratoplasty. *Br J Ophthalmol*. 2011;95:1509–1512.
23. Bhalerao SA, Mohamed A, Vaddavalli PK, et al. Outcomes of rebubbling for graft detachment after Descemet's stripping endothelial keratoplasty or Descemet's stripping automated endothelial keratoplasty. *Indian J Ophthalmol*. 2020;68:48–53.
24. Gerber-Hollbach N, Baydoun L, López EF, et al. Clinical outcome of rebubbling for graft detachment after Descemet membrane endothelial keratoplasty. *Cornea*. 2017;36:771–776.
25. Parekh M, Leon P, Ruzza A, et al. Graft detachment and rebubbling rate in Descemet membrane endothelial keratoplasty. *Surv Ophthalmol*. 2018;63:245–250.
26. Guerra FP, Anshu A, Price MO, et al. Descemet's membrane endothelial keratoplasty: prospective study of 1-year visual outcomes, graft survival, and endothelial cell loss. *Ophthalmology*. 2011;118:2368–2373.
27. Busin M, Madi S, Santorum P, et al. Ultrathin Descemet's stripping automated endothelial keratoplasty with the microkeratome double-pass technique: two-year outcomes. *Ophthalmology*. 2013;120:1186–1194.
28. Price MO, Calhoun P, Kollman C, et al. Descemet stripping endothelial keratoplasty: ten-year endothelial cell loss compared with penetrating keratoplasty. *Ophthalmology*. 2016;123:1421–1427.
29. Lass JH, Benetz BA, Verdier DD, et al; Cornea Preservation Time Study Group. Corneal endothelial cell loss 3 years after successful Descemet stripping automated endothelial keratoplasty in the cornea preservation time study: a randomized clinical trial. *JAMA Ophthalmol*. 2017;135:1394–1400.
30. Wacker K, Baratz KH, Maguire LJ, et al. Descemet stripping endothelial keratoplasty for fuchs' endothelial corneal dystrophy: five-year results of a prospective study. *Ophthalmology*. 2016;123:154–160.
31. Price DA, Kelley M, Price FW Jr, et al. Five-year graft survival of Descemet membrane endothelial keratoplasty (EK) versus Descemet stripping EK and the effect of donor sex matching. *Ophthalmology*. 2018;125:1508–1514.
32. Patel SV, Lass JH, Benetz BA, et al; Cornea Preservation Time Study Group. Postoperative endothelial cell density is associated with late endothelial graft failure after Descemet stripping automated endothelial keratoplasty. *Ophthalmology*. 2019;126:1076–1083.
33. Price MO, Gorovoy M, Price FW Jr, et al. Descemet's stripping automated endothelial keratoplasty: three-year graft and endothelial cell survival compared with penetrating keratoplasty. *Ophthalmology*. 2013;120:246–251.
34. Lass JH, Gal RL, et al; Cornea Donor Study Investigator Group. Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. *Ophthalmology*. 2008;115:627–632.e8.
35. Lass JH, Benetz BA, et al; Writing Committee for the Cornea Donor Study Research Group. Donor age and factors related to endothelial cell loss 10 years after penetrating keratoplasty: specular microscopy ancillary study. *Ophthalmology*. 2013;120:2428–2435.
36. Anshu A, Price MO, Price FW Jr. Risk of corneal transplant rejection significantly reduced with Descemet's membrane endothelial keratoplasty. *Ophthalmology*. 2012;119:536–540.
37. Di Zazzo A, Kheirkhah A, Abud TB, et al. Management of high-risk corneal transplantation. *Surv Ophthalmol*. 2017;62:816–827.
38. Hos D, Matthaei M, Bock F, et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. *Prog Retin Eye Res*. 2019;73:100768.
39. Stulting RD, Lass JH, Terry MA, et al; Cornea Preservation Time Study Group. Factors associated with graft rejection in the cornea preservation time study. *Am J Ophthalmol*. 2018;196:197–207.

40. Nahum Y, Mimouni M, Busin M. Risk factors predicting the need for graft exchange after Descemet stripping automated endothelial keratoplasty. *Cornea*. 2015;34:876–879.
41. Hos D, Tuac O, Schaub F, et al. Incidence and clinical course of immune reactions after Descemet membrane endothelial keratoplasty: retrospective analysis of 1000 consecutive eyes. *Ophthalmology*. 2017;124:512–518.
42. Al-Mezaine H, Wagoner MD; King Khaled Eye Specialist Hospital Cornea Transplant Study Group. Repeat penetrating keratoplasty: indications, graft survival, and visual outcome. *Br J Ophthalmol*. 2006;90:324–327.
43. The Collaborative Corneal Transplantation Studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The Collaborative Corneal Transplantation Studies Research Group. *Arch Ophthalmol*. 1992;110:1392–403.
44. Aboshiha J, Jones MNA, Hopkinson CL, et al. Differential survival of penetrating and lamellar transplants in management of failed corneal grafts. *JAMA Ophthalmol*. 2018;136:859–865.
45. Bersudsky V, Blum-Hareuveni T, Rehany U, et al. The profile of repeated corneal transplantation. *Ophthalmology*. 2001;108:461–469.
46. Armitage WJ, Goodchild C, Griffin MD, et al. High-risk corneal transplantation: recent developments and future possibilities. *Transplantation*. 2019;103:2468–2478.
47. Anshu A, Price MO, Price FW Jr. Descemet's stripping endothelial keratoplasty under failed penetrating keratoplasty: visual rehabilitation and graft survival rate. *Ophthalmology*. 2011;118:2155–2160.
48. Mitry D, Bhogal M, Patel AK, et al. Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome. *JAMA Ophthalmol*. 2014;132:742–749.
49. Ang M, Ho H, Wong C, et al. Endothelial keratoplasty after failed penetrating keratoplasty: an alternative to repeat penetrating keratoplasty. *Am J Ophthalmol*. 2014;158:1221–1227.e1.
50. Anshu A, Price MO, Price FW Jr. Descemet membrane endothelial keratoplasty and hybrid techniques for managing failed penetrating grafts. *Cornea*. 2013;32:1–4.
51. Güell JL, Morral M, Barbany M, et al. Descemet membrane endothelial keratoplasty after penetrating keratoplasty. *J EuCornea*. 2019;2:10–13.
52. Woo JH, Ang M, Htoon HM, et al. Descemet membrane endothelial keratoplasty versus Descemet stripping automated endothelial keratoplasty and penetrating keratoplasty. *Am J Ophthalmol*. 2019;207:288–303.
53. Schrittenlocher S, Schlereth SL, Siebelmann S, et al. Long-term outcome of Descemet membrane endothelial keratoplasty (DMEK) following failed penetrating keratoplasty (PK). *Acta Ophthalmol*. 2020;98:e901–e906.
54. Wang F, Zhang T, Kang YW, et al. Endothelial keratoplasty versus repeat penetrating keratoplasty after failed penetrating keratoplasty: a systematic review and meta-analysis. *PLoS One*. 2017;12:e0180468.
55. Moura-Coelho N, Manero F, Elies D, et al. Repeat Descemet membrane endothelial keratoplasty for failed primary DMEK at a referral center for keratoplasty in Spain: DIMOEK study. *Am J Ophthalmol*. 2020;215:49–55.
56. Zafar S, Wang P, Woreta FA, et al. Risk factors for repeat keratoplasty after endothelial keratoplasty in the medicare population. *Am J Ophthalmol*. 2020;221:287–298.
57. Yazu H, Yamaguchi T, Dogru M, et al. Decreased visual acuity by an irregular corneal posterior surface after repeat Descemet stripping automated endothelial keratoplasty. *Eye Contact Lens*. 2018;44(suppl 1):S249–S254.
58. Dirisamer M, Acis G, Dapena I, et al. Secondary "thin-DSEK" after long-term graft failure in DLEK: a double transplanted cornea. *Cornea*. 2011;30:828–831.
59. Kim P, Brodbaker E, Lichtinger A, et al. Outcomes of repeat endothelial keratoplasty in patients with failed deep lamellar endothelial keratoplasty. *Cornea*. 2011;30:1183–1186.
60. Agha B, Dawson DG, Kohnen T, et al. Corneal densitometry after secondary Descemet membrane endothelial keratoplasty. *Cornea*. 2019;38:1083–1092.
61. Gorovoy MS, Meisler DM, Dupps WJ Jr. Late repeat Descemet-stripping automated endothelial keratoplasty. *Cornea*. 2008;27:238–240.
62. Lee JA, Djalilian AR, Riaz KM, et al. Clinical and histopathologic features of failed Descemet stripping automated endothelial keratoplasty grafts. *Cornea*. 2009;28:530–535.
63. Letko E, Price DA, Lindoso EM, et al. Secondary graft failure and repeat endothelial keratoplasty after Descemet's stripping automated endothelial keratoplasty. *Ophthalmology*. 2011;118:310–314.
64. Kim P, Yeung SN, Lichtinger A, et al. Outcomes of repeat endothelial keratoplasty in patients with failed Descemet stripping endothelial keratoplasty. *Cornea*. 2012;31:1154–1157.
65. Ghosh S, Bonshek R, Morgan SJ. Histologically proven epithelial ingrowth in failed Descemet stripping automated endothelial keratoplasty (DSAEK) managed by repeat DSAEK. *Clin Ophthalmol*. 2013;7:1035–1040.
66. Nahum Y, Mimouni M, Madi S, et al. Visual outcomes of repeat versus primary Descemet stripping automated endothelial keratoplasty—a paired comparison. *Cornea*. 2016;35:592–595.
67. Dickman MM, Spekreijse LS, Dunker SL, et al. Long-term outcomes of repeated corneal transplantations: a prospective Dutch registry study. *Am J Ophthalmol*. 2018;193:156–165.
68. Thompson JM, Truong AH, Stern HD, et al. A multicenter study evaluating the risk factors and outcomes of repeat Descemet stripping endothelial keratoplasty. *Cornea*. 2019;38:177–182.
69. Matsumoto K, Kitazawa K, Wakimasu K, et al. Repeat DSAEK with intraocular lens implantation in a case of failed DSAEK with previous phakic intraocular lens implantation. *JCRS Online Case Reports*. 2019;7:71–73.
70. Kaur M, Titiyal JS, Gagrani M, et al. Repeat keratoplasty in failed Descemet stripping automated endothelial keratoplasty. *Indian J Ophthalmol*. 2019;67:1586–1592.
71. Turnbull AM, Tsatsos M, Hossain PN, et al. Determinants of visual quality after endothelial keratoplasty. *Surv Ophthalmol*. 2016;61:257–271.
72. Muftuoglu O, Prasher P, Bowman RW, et al. Corneal higher-order aberrations after Descemet's stripping automated endothelial keratoplasty. *Ophthalmology*. 2010;117:878–884.e6.
73. Duggan MJ, Rose-Nussbaumer J, Lin CC, et al. Corneal higher-order aberrations in Descemet membrane endothelial keratoplasty versus ultrathin DSAEK in the Descemet endothelial thickness comparison trial: a randomized clinical trial. *Ophthalmology*. 2019;126:946–957.
74. Brockmann T, Brockmann C, Maier AK, et al. Descemet membrane endothelial keratoplasty for graft failure after Descemet stripping endothelial keratoplasty: clinical results and histopathologic findings. *JAMA Ophthalmol*. 2015;133:813–819.
75. Kamiya K, Asato H, Shimizu K, et al. Effect of intraocular forward scattering and corneal higher-order aberrations on visual acuity after Descemet's stripping automated endothelial keratoplasty. *PLoS One*. 2015;10:e0131110.
76. Feizi S, Javadi MA. Effect of donor graft thickness on clinical outcomes after Descemet stripping automated endothelial keratoplasty. *J Ophthalmic Vis Res*. 2019;14:18–26.
77. Rudolph M, Laaser K, Bachmann BO, et al. Corneal higher-order aberrations after Descemet's membrane endothelial keratoplasty. *Ophthalmology*. 2012;119:528–535.
78. Ashar J, Mathur A, Garg P. Repeat endothelial keratoplasty. *Ophthalmology*. 2011;118:1899–1900; author reply 1900.
79. Kim RS, Kim G. Double Descemet stripping automated endothelial keratoplasty (DSAEK): secondary DSAEK without removal of the failed primary DSAEK graft. *Ophthalmology*. 2019;126:1218.
80. Yoeruek E, Bartz-Schmidt KU. Secondary Descemet membrane endothelial keratoplasty after failed primary Descemet membrane endothelial keratoplasty: clinical results. *Cornea*. 2013;32:1414–1417.
81. Ćirković A, Schlötzer-Schrehardt U, Weller J.M, et al. Clinical and ultrastructural characteristics of graft failure in DMEK: 1-year results after repeat DMEK. *Cornea*. 2015;34:11–7.
82. Baydoun L, van Dijk K, Dapena I, et al. Repeat Descemet membrane endothelial keratoplasty after complicated primary Descemet membrane endothelial keratoplasty. *Ophthalmology*. 2015;122:8–16.
83. Price MO, Feng MT, McKee Y, et al. Repeat Descemet membrane endothelial keratoplasty: secondary grafts with early intervention are comparable with fellow-eye primary grafts. *Ophthalmology*. 2015;122:1639–1644.
84. Alió Del Barrio JL, Vega-Estrada A, Alió JL. Descemet membrane endothelial keratoplasty (DMEK) under previous DMEK for secondary endothelial graft failure. *Cornea*. 2018;37:793–795.
85. Agha B, Shajari M, Slavik-Lencova A, et al. Functional outcome of repeat Descemet membrane endothelial keratoplasty (DMEK) for corneal decompensation following graft failure after primary DMEK. *Clin Ophthalmol*. 2019;13:477–482.

86. Lužnik Z, Oellerich S, Roesch K, et al. Descemet membrane endothelial keratoplasty failure associated with innate immune activation. *Ophthalmology*. 2019;126:1462–1464.
87. Schmidt I, Schlötzer-Schrehardt U, Langenbucher A, et al. Ultrastructural findings in graft failure after Descemet membrane endothelial keratoplasty (DMEK) and new triple procedure. *Medicine (Baltimore)*. 2019;98:e15493.
88. Ham L, Dapena I, van der Wees J, et al. Secondary DMEK for poor visual outcome after DSEK: donor posterior stroma may limit visual acuity in endothelial keratoplasty. *Cornea*. 2010;29:1278–1283.
89. Dirisamer M, Parker J, Naveiras M, et al. Identifying causes for poor visual outcome after DSEK/DSAEK following secondary DMEK in the same eye. *Acta Ophthalmol*. 2013;91:131–139.
90. Weller JM, Tourtas T, Kruse FE, et al. Descemet membrane endothelial keratoplasty as treatment for graft failure after Descemet stripping automated endothelial keratoplasty. *Am J Ophthalmol*. 2015;159:1050–1057.e2.
91. Sorkin N, Showail M, Einan-Lifshitz A, et al. Outcomes of Descemet membrane endothelial keratoplasty in eyes with a previous Descemet stripping automated endothelial keratoplasty graft. *Cornea*. 2018;37:678–681.
92. Agha B, Shajari M, Slavik-Lencova A, et al. Outcome of Descemet membrane endothelial keratoplasty for graft failure after Descemet stripping automated endothelial keratoplasty. *Clin Ophthalmol*. 2019;13:553–559.
93. Dapena I, Ham L, van Luijk C, et al. Back-up procedure for graft failure in Descemet membrane endothelial keratoplasty (DMEK). *Br J Ophthalmol*. 2010;94:241–244.
94. Arnalich-Montiel F, Hernández-Verdejo JL, Oblanca N, et al. Comparison of corneal haze and visual outcome in primary DSAEK versus DSAEK following failed DMEK. *Graefes Arch Clin Exp Ophthalmol*. 2013;251:2575–2584.
95. Graffi S, Leon P, Nahum Y, et al. Outcomes of ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) performed in eyes with failure of primary Descemet membrane endothelial keratoplasty (DMEK). *Br J Ophthalmol*. 2019;103:599–603.
96. Price MO, Scanameo A, Feng MT, et al. Descemet's membrane endothelial keratoplasty: risk of immunologic rejection episodes after discontinuing topical corticosteroids. *Ophthalmology*. 2016;123:1232–1236.
97. Chatel MA, Larkin DF. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk. *Am J Ophthalmol*. 2010;150:179–184.
98. Abudou M, Wu T, Evans JR, et al. Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty. *Cochrane Database Syst Rev*. 2015:CD007603.
99. Tan TE, Tan DTH. Cytomegalovirus corneal endotheliitis after Descemet membrane endothelial keratoplasty. *Cornea*. 2019;38:413–418.
100. Yin D, Huang A, Warrow D, et al. Detection of herpes simplex virus type 1 in failed Descemet stripping automated endothelial keratoplasty grafts. *Cornea*. 2013;32:1189–1192.
101. Zarei-Ghanavati S, Alizadeh R, Yoo SH. Herpes simplex virus endotheliitis following Descemet's membrane endothelial keratoplasty. *J Ophthalmic Vis Res*. 2015;10:184–186.
102. da Costa Paula CA, Gore DM, Shah K, et al. Cytomegalovirus infection is not a major cause of corneal graft failure in the United Kingdom. *Eye (Lond)*. 2019;33:833–837.
103. Anshu A, Chee SP, Mehta JS, et al. Cytomegalovirus endotheliitis in Descemet's stripping endothelial keratoplasty. *Ophthalmology*. 2009;116:624–630.
104. Ang M, Sng CCA, Chee SP, et al. Outcomes of corneal transplantation for irreversible corneal decompensation secondary to corneal endotheliitis in Asian eyes. *Am J Ophthalmol*. 2013;156:260–266.e2.
105. Morishige N, Morita Y, Yamada N, et al. Differential changes in intraocular pressure and corneal manifestations in individuals with viral endotheliitis after keratoplasty. *Cornea*. 2016;35:602–606.
106. Abdelmassih Y, Dubrulle P, Sitbon C, et al. Therapeutic challenges and prognosis of Descemet's membrane endothelial keratoplasty in herpes simplex eye disease. *Cornea*. 2019;38:553–558.
107. Basak SK, Basak S. Descemet membrane endothelial keratoplasty in irreversible corneal edema due to herpes simplex virus endotheliitis. *Cornea*. 2020;39:8–12.
108. Friehmann A, Myerscough J, Giannaccare G, et al. Successful Descemet membrane endothelial keratoplasty in proven herpetic endothelial decompensation requires intensive antiviral therapy. *Cornea*. 2020;39:196–199.
109. Hsiao CH, Hwang YS, Chuang WY, et al. Prevalence and clinical consequences of cytomegalovirus DNA in the aqueous humour and corneal transplants. *Br J Ophthalmol*. 2019;103:666–671.
110. Chew MC, Tan DT, Chee SP, et al. Optimising graft survival in endothelial keratoplasty for endothelial failure secondary to cytomegalovirus endotheliitis. *J Ophthalmic Inflamm Infect*. 2019;9:15.
111. Basilious A, Chew HF. Topical ganciclovir for prophylaxis of cytomegalovirus endotheliitis in endothelial keratoplasty. *Cornea*. 2019;38:120–122.
112. Asberg A, Humar A, Rollag H, et al; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. *Am J Transplant*. 2007;7:2106–2113.
113. Vanathi M, Sharma N, Sinha R, et al. Indications and outcome of repeat penetrating keratoplasty in India. *BMC Ophthalmol*. 2005;5:26.
114. Yalniz-Akkaya Z, Burcu Nurozler A, Yildiz E, et al. Repeat penetrating keratoplasty: indications and prognosis, 1995-2005. *Eur J Ophthalmol*. 2009;19:362–368.
115. Kinoshita S, Koizumi N, Ueno M, et al. Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. *N Engl J Med*. 2018;378:995–1003.
116. Moura-Coelho N, Tavares Ferreira J, Bruxelas CP, et al. Rho kinase inhibitors—a review on the physiology and clinical use in Ophthalmology. *Graefes Arch Clin Exp Ophthalmol*. 2019;257:1101–1117.